Yan Li1, Fang-Fei Wei1, Lutgarde Thijs1, José Boggia1, Kei Asayama1, Tine W Hansen1, Masahiro Kikuya1, Kristina Björklund-Bodegård1, Takayoshi Ohkubo1, Jørgen Jeppesen1, Yu-Mei Gu1, Christian Torp-Pedersen1, Eamon Dolan1, Yan-Ping Liu1, Tatiana Kuznetsova1, Katarzyna Stolarz-Skrzypek1, Valérie Tikhonoff1, Sofia Malyutina1, Edoardo Casiglia1, Yuri Nikitin1, Lars Lind1, Edgardo Sandoya1, Kalina Kawecka-Jaszcz1, Luis Mena1, Gladys E Maestre1, Jan Filipovský1, Yutaka Imai1, Eoin O'Brien1, Ji-Guang Wang1, Jan A Staessen1. 1. From the Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluations, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (Y.L., F.-F.W., J.-G.W.); Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (L.T., Y.-M.G., Y.-P.L., T.K., J.A.S.); Centro de Nefrología and Departamento de Fisiopatología, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay (J.B.); Tohoku University Graduate School of Pharmaceutical Sciences and Medicine, Sendai, Japan (K.A., M.K., T.O., Y.I.); Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan (K.A., T.O.); Research Center for Prevention and Health and Steno Diabetes Center, Gentofte, Denmark (T.W.H.); Division of Cardiovascular Medicine, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden (K.B.-B.); Department of Medicine, Glostrup Hopsital, University of Copenhagen, Copenhagen, Denmark (J.J.); Copenhagen University Hospital, Copenhagen, Denmark (C.-T.P.); Cambridge University Hospitals, Addenbrook's Hospital, Cambridge, United Kingdom (E.D.); First Department of Cardiology, Interventional Electrocardiology and Hypertension, Jagiellonian University Medical College, Kraków, Poland (K.S.-S., K.K.-J.); Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy (V.T., E.C.); Institute of Internal Medicine, Novosibirsk, Russian Federation (S.M., Y.N.); Section of Geriatrics, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden (L.L.); Asociación Española Primera de Socorros Mutuos, Montevideo, Uruguay (E.S.); Laboratorio de Neurociencias and Instituto Cardiovascular, Universidad del Zulia, Maracaibo, Venezuela (L.M., G.E.M.); Faculty
Abstract
BACKGROUND: Data on risk associated with 24-hour ambulatory diastolic (DBP24) versus systolic (SBP24) blood pressure are scarce. METHODS AND RESULTS: We recorded 24-hour blood pressure and health outcomes in 8341 untreated people (mean age, 50.8 years; 46.6% women) randomly recruited from 12 populations. We computed hazard ratios (HRs) using multivariable-adjusted Cox regression. Over 11.2 years (median), 927 (11.1%) participants died, 356 (4.3%) from cardiovascular causes, and 744 (8.9%) experienced a fatal or nonfatal cardiovascular event. Isolated diastolic hypertension (DBP24≥80 mm Hg) did not increase the risk of total mortality, cardiovascular mortality, or stroke (HRs≤1.54; P≥0.18), but was associated with a higher risk of fatal combined with nonfatal cardiovascular, cardiac, or coronary events (HRs≥1.75; P≤0.0054). Isolated systolic hypertension (SBP24≥130 mm Hg) and mixed diastolic plus systolic hypertension were associated with increased risks of all aforementioned end points (P≤0.0012). Below age 50, DBP24 was the main driver of risk, reaching significance for total (HR for 1-SD increase, 2.05; P=0.0039) and cardiovascular mortality (HR, 4.07; P=0.0032) and for all cardiovascular end points combined (HR, 1.74; P=0.039) with a nonsignificant contribution of SBP24 (HR≤0.92; P≥0.068); above age 50, SBP24 predicted all end points (HR≥1.19; P≤0.0002) with a nonsignificant contribution of DBP24 (0.96≤HR≤1.14; P≥0.10). The interactions of age with SBP24 and DBP24 were significant for all cardiovascular and coronary events (P≤0.043). CONCLUSIONS: The risks conferred by DBP24 and SBP24 are age dependent. DBP24 and isolated diastolic hypertension drive coronary complications below age 50, whereas above age 50 SBP24 and isolated systolic and mixed hypertension are the predominant risk factors.
BACKGROUND: Data on risk associated with 24-hour ambulatory diastolic (DBP24) versus systolic (SBP24) blood pressure are scarce. METHODS AND RESULTS: We recorded 24-hour blood pressure and health outcomes in 8341 untreated people (mean age, 50.8 years; 46.6% women) randomly recruited from 12 populations. We computed hazard ratios (HRs) using multivariable-adjusted Cox regression. Over 11.2 years (median), 927 (11.1%) participants died, 356 (4.3%) from cardiovascular causes, and 744 (8.9%) experienced a fatal or nonfatal cardiovascular event. Isolated diastolic hypertension (DBP24≥80 mm Hg) did not increase the risk of total mortality, cardiovascular mortality, or stroke (HRs≤1.54; P≥0.18), but was associated with a higher risk of fatal combined with nonfatal cardiovascular, cardiac, or coronary events (HRs≥1.75; P≤0.0054). Isolated systolic hypertension (SBP24≥130 mm Hg) and mixed diastolic plus systolic hypertension were associated with increased risks of all aforementioned end points (P≤0.0012). Below age 50, DBP24 was the main driver of risk, reaching significance for total (HR for 1-SD increase, 2.05; P=0.0039) and cardiovascular mortality (HR, 4.07; P=0.0032) and for all cardiovascular end points combined (HR, 1.74; P=0.039) with a nonsignificant contribution of SBP24 (HR≤0.92; P≥0.068); above age 50, SBP24 predicted all end points (HR≥1.19; P≤0.0002) with a nonsignificant contribution of DBP24 (0.96≤HR≤1.14; P≥0.10). The interactions of age with SBP24 and DBP24 were significant for all cardiovascular and coronary events (P≤0.043). CONCLUSIONS: The risks conferred by DBP24 and SBP24 are age dependent. DBP24 and isolated diastolic hypertension drive coronary complications below age 50, whereas above age 50 SBP24 and isolated systolic and mixed hypertension are the predominant risk factors.
Authors: Timo E Strandberg; Veikko V Salomaa; Hannu T Vanhanen; Kaisu Pitkälä; Tatu A Miettinen Journal: J Hypertens Date: 2002-03 Impact factor: 4.844
Authors: Giuseppe Mancia; Guy De Backer; Anna Dominiczak; Renata Cifkova; Robert Fagard; Giuseppe Germano; Guido Grassi; Anthony M Heagerty; Sverre E Kjeldsen; Stephane Laurent; Krzysztof Narkiewicz; Luis Ruilope; Andrzej Rynkiewicz; Roland E Schmieder; Harry A J Struijker Boudier; Alberto Zanchetti; Alec Vahanian; John Camm; Raffaele De Caterina; Veronica Dean; Kenneth Dickstein; Gerasimos Filippatos; Christian Funck-Brentano; Irene Hellemans; Steen Dalby Kristensen; Keith McGregor; Udo Sechtem; Sigmund Silber; Michal Tendera; Petr Widimsky; Jose Luis Zamorano; Sverre E Kjeldsen; Serap Erdine; Krzysztof Narkiewicz; Wolfgang Kiowski; Enrico Agabiti-Rosei; Ettore Ambrosioni; Renata Cifkova; Anna Dominiczak; Robert Fagard; Anthony M Heagerty; Stephane Laurent; Lars H Lindholm; Giuseppe Mancia; Athanasios Manolis; Peter M Nilsson; Josep Redon; Roland E Schmieder; Harry A J Struijker-Boudier; Margus Viigimaa; Gerasimos Filippatos; Stamatis Adamopoulos; Enrico Agabiti-Rosei; Ettore Ambrosioni; Vicente Bertomeu; Denis Clement; Serap Erdine; Csaba Farsang; Dan Gaita; Wolfgang Kiowski; Gregory Lip; Jean-Michel Mallion; Athanasios J Manolis; Peter M Nilsson; Eoin O'Brien; Piotr Ponikowski; Josep Redon; Frank Ruschitzka; Juan Tamargo; Pieter van Zwieten; Margus Viigimaa; Bernard Waeber; Bryan Williams; Jose Luis Zamorano Journal: Eur Heart J Date: 2007-06-11 Impact factor: 29.983
Authors: Gladys E Maestre; Gloria Pino-Ramírez; Aldrin E Molero; Eglé R Silva; Raquel Zambrano; Luis Falque; María P Gamero; Tulio A Sulbarán Journal: Neuroepidemiology Date: 2002 Jul-Aug Impact factor: 3.282
Authors: John W McEvoy; Nilanjan Chatterjee; Brian P McGrath; Prosenjit Kundu; Natalie Daya; Josef Coresh; Elizabeth Selvin Journal: Hypertension Date: 2020-07-27 Impact factor: 10.190
Authors: Yuichiro Yano; Jared P Reis; Yacob G Tedla; David C Goff; David R Jacobs; Stephen Sidney; Hongyan Ning; Kiang Liu; Philip Greenland; Donald M Lloyd-Jones Journal: JAMA Cardiol Date: 2017-04-01 Impact factor: 14.676
Authors: John P Kirwan; Steven K Malin; Amanda R Scelsi; Emily L Kullman; Sankar D Navaneethan; Mangesh R Pagadala; Jacob M Haus; Julianne Filion; Jean-Philippe Godin; Sunil Kochhar; Alastair B Ross Journal: J Nutr Date: 2016-10-19 Impact factor: 4.798
Authors: S Justin Thomas; John N Booth; Samantha G Bromfield; Samantha R Seals; Tanya M Spruill; Gbenga Ogedegbe; Srividya Kidambi; Daichi Shimbo; David Calhoun; Paul Muntner Journal: J Am Soc Hypertens Date: 2017-02-16
Authors: Elizabeth R Bertone-Johnson; Serena C Houghton; Brian W Whitcomb; Lynnette L Sievert; Sofija E Zagarins; Alayne G Ronnenberg Journal: J Womens Health (Larchmt) Date: 2016-07-15 Impact factor: 2.681